The David Geffen Galleries building, the newest of four that constitute the Los Angeles County Museum of Art, is a work of furious originality and ambition. It is the most significant American museum ...

After finding Still Water in an outer room behind the West Gate, you'll find yourself in one of the trippier areas in Blue Prince. The Atelier Maze is easily one of the most confusing areas in the ...

Nahda Nabiilah is a writer and editor from Indonesia. She has always loved writing and playing games, so one day she decided to combine the two. Most of the time, writing gaming guides is a blast for ...

Unlock the full InfoQ experience by logging in! Stay updated with your favorite authors and topics, engage with content, and download exclusive resources. Dany Lepage discusses the architectural ...

Chris is a Senior News Writer for Collider. He can be found in an IMAX screen, with his eyes watering and his ears bleeding for his own pleasure. He joined the news team in 2022 and accidentally fell ...

Maze Therapeutics leverages its Compass platform to translate human genetic insights into de-risked, high-probability drug candidates. MZE829 targets APOL1-mediated kidney disease with a dual ...

JDK 27, due in September, kicks off with a post-quantum hybrid key exchange proposal to bolster the security of network communications. Java Development Kit (JDK) 27, a release of standard Java ...

When I last covered the self-styled TechBio company Recursion Pharmaceuticals, Inc. (RXRX) in early October, I was attempting to find reasons why the company's share price was on the rise, up from ~$4 ...

Unlock the full InfoQ experience by logging in! Stay updated with your favorite authors and topics, engage with content, and download exclusive resources. Dany Lepage discusses the architectural ...

Monday - Friday, 6:00 - 7:00 PM ET It's that time again! "Mad Money" host Jim Cramer rings the lightning round bell, which means he's giving his answers to callers' stock questions at rapid speed.

Monday - Friday, 2:00 - 3:00 PM ET In this article Maze Therapeutics has had a great run since its initial public offering in January — and CEO Jason Coloma is hoping that momentum continues as the ...